NRx Pharmaceuticals, Inc. (NRXPW)Wilmington, United States | NasdaqCM
0.00 USD
+0.00
(0.000%)
⇧
(May 22, 2026, 3:04 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 2:39 a.m. EDT
The immediate outlook is severely bearish due to a catastrophic collapse in liquidity and capital structure. The stock trades at $0.0026, which coincides with the 52-week low, indicating a complete lack of upward momentum or trading interest. Fundamentally, the company is in distress with negative book value (-$0.41), massive free cash burn (-$8.5M), and a current ratio of 0.29, signaling an imminent inability to meet short-term obligations. There is no evidence of a turnaround; instead, the balance sheet shows eroding equity and deep losses. Furthermore, the price history is insufficient to establish any multi-year trend, and the absence of a dividend confirms the company cannot generate shareholder returns. This is a high-risk speculative vehicle with no safety margin. |
| Attribute | Value |
|---|---|
| Revenue per Share | 0.09 |
| Beta | 2.02 |
| Previous Name | NeuroRx, Inc. |
| Website | https://www.nrxpharma.com |
| Attribute | Value |
|---|---|
| Address1 | 1,201 N. Market Street |
| Address2 | Suite 111 |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | 2.017 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | -0.413 |
| City | Wilmington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.0026 |
| Current Ratio | 0.292 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.0033 |
| Day Low | 0.0026 |
| Display Name | NRx Pharmaceuticals |
| Ebitda | -17,057,000 |
| Ebitda Margins | 0.0 |
| Eps Trailing Twelve Months | -6.247 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.0033 |
| Fifty Two Week High Change | -0.0007 |
| Fifty Two Week High Change Percent | -0.2121212 |
| Fifty Two Week Low | 0.0026 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.0026 - 0.0033 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,779,975,000,000 |
| Float Shares | 30,449,967 |
| Free Cashflow | -8,542,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 29 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.50458 |
| Gross Profits | 1,157,000 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Language | en-US |
| Long Business Summary | NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware. |
| Long Name | NRx Pharmaceuticals, Inc. |
| Market | us_market |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_319388181 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -24,540,000 |
| Open | 0.1602 |
| Operating Cashflow | -14,927,000 |
| Operating Margins | -4.44569 |
| Phone | 484 254 6134 |
| Prev Name | NeuroRx, Inc. |
| Previous Close | 0.0 |
| Price Hint | 4 |
| Price To Book | -0.0062953997 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.274 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0026 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.0033 |
| Regular Market Day Low | 0.0026 |
| Regular Market Day Range | 0.0026 - 0.0033 |
| Regular Market Open | 0.1602 |
| Regular Market Previous Close | 0.0 |
| Regular Market Price | 0.0026 |
| Regular Market Time | 1,779,476,669 |
| Regular Market Volume | 176,260 |
| Return On Assets | -1.10225 |
| Revenue Per Share | 0.09 |
| Sand P52 Week Change | 0.20847368 |
| Sector | |
| Sector Key | |
| Source Interval | 15 |
| State | DE |
| Symbol | NRXPW |
| Total Cash | 6,713,000 |
| Total Cash Per Share | 0.185 |
| Total Debt | 934,000 |
| Total Revenue | 2,293,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -6.247 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 176,260 |
| Website | https://www.nrxpharma.com |
| Zip | 19,801 |